Kadmon, a Sanofi Company, is a biopharmaceutical company that discovers, develops and markets transformative therapies for un ... met medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Our late-stage product candidate, belumosudil, is an orally administered selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) in development for the treatment of inflammatory and fibrotic diseases. A pivotal study of belumosudil is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 study in systemic sclerosis. Kadmon is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. Our lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein in a Phase 1 clinical trial. read more